Image Source: AsiaOne
Novavax and Serum Institute of India Announce Development and Commercial Collaboration GlobeNewswire August 06, 2020 Expected to support minimum of 1 billion doses of NVX-CoV2373 for India and low- and middle-income countriesLeverages Serum Institute’s existing reach and infrastructure Builds on and complements Novavax-CEPI collaboration to develop and distribute NVX-CoV2373 for low- and middle-income countries through the COVAX FacilitySerum Institute gains exclusive rights to commercialize in India and non-exclusive rights to commercialize in other LMIC countriesImportant first step in ensuring global supply during worldwide pandemic GAITHERSBURG, Md., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc.
Source: AsiaOne